A phase-I, open label clinical trial to assess the safety of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine manufactured by Serum Institute of India Pvt. Ltd. in healthy Indian adults

Trial Profile

A phase-I, open label clinical trial to assess the safety of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine manufactured by Serum Institute of India Pvt. Ltd. in healthy Indian adults

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs DTaP vaccine (Primary)
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Adverse reactions
  • Sponsors Serum Institute of India
  • Most Recent Events

    • 18 Jul 2017 Status changed from not yet recruiting to completed.
    • 22 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top